3.19
price up icon5.63%   0.17
pre-market  Pre-market:  3.05   -0.14   -4.39%
loading
Immuneering Corp stock is traded at $3.19, with a volume of 1.24M. It is up +5.63% in the last 24 hours and up +107.14% over the past month. Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
See More
Previous Close:
$3.02
Open:
$3.09
24h Volume:
1.24M
Relative Volume:
1.94
Market Cap:
$78.09M
Revenue:
$317.00K
Net Income/Loss:
$-53.47M
P/E Ratio:
-1.6878
EPS:
-1.89
Net Cash Flow:
$-49.31M
1W Performance:
+15.16%
1M Performance:
+107.14%
6M Performance:
+46.33%
1Y Performance:
+131.16%
1-Day Range:
Value
$2.92
$3.20
1-Week Range:
Value
$2.29
$3.24
52-Week Range:
Value
$1.00
$3.83

Immuneering Corp Stock (IMRX) Company Profile

Name
Name
Immuneering Corp
Name
Phone
617-500-8080
Name
Address
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Name
Employee
54
Name
Twitter
Name
Next Earnings Date
2025-03-19
Name
Latest SEC Filings
Name
IMRX's Discussions on Twitter

Compare IMRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IMRX
Immuneering Corp
3.19 78.09M 317.00K -53.47M -49.31M -1.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
443.40 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
318.25 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.04 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
254.49 28.51B 3.81B -644.79M -669.77M -6.24

Immuneering Corp Stock (IMRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-13-24 Downgrade Morgan Stanley Equal-Weight → Underweight
Mar-15-24 Downgrade Jefferies Buy → Hold
Mar-15-24 Reiterated Needham Buy
Mar-15-24 Downgrade TD Cowen Outperform → Market Perform
Dec-01-23 Initiated Needham Buy
Jun-26-23 Resumed Oppenheimer Outperform
Apr-19-23 Upgrade Mizuho Neutral → Buy
Apr-19-23 Upgrade Morgan Stanley Underweight → Equal-Weight
Mar-30-23 Initiated Mizuho Neutral
Feb-03-23 Downgrade Morgan Stanley Equal-Weight → Underweight
Jul-08-22 Initiated Chardan Capital Markets Buy
Apr-01-22 Initiated Oppenheimer Outperform
Jan-07-22 Initiated Piper Sandler Overweight
View All

Immuneering Corp Stock (IMRX) Latest News

pulisher
Jun 18, 2025

Immuneering (IMRX) Target Price Raised by Mizuho Analyst | IMRX Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Chardan Capital Maintains Buy Rating on IMRX with $13 Price Targ - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Metric Deep Dive: Understanding La Rosa Holdings Corp (LRHC) Through its Ratios - DWinneX

Jun 18, 2025
pulisher
Jun 18, 2025

Financial Analysis: TNL Mediagene (TNMG)’s Ratios Unveil Key Insights - DWinneX

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering (IMRX) Price Target Raised by Mizuho Following Positive Trial Data | IMRX Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering stock price target raised to $10 at Mizuho on cancer drug data - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering's Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - MENAFN.com

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering’s Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - Asianet Newsable

Jun 18, 2025
pulisher
Jun 17, 2025

Immuneering’s atebimetinibin shows positive survival data in pancreatic cancer - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Immuneering stock rises after positive pancreatic cancer trial data - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

Immuneering (IMRX) Reports Promising Phase 2a Trial Results for Pancreatic Cancer Treatment | IMRX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Pancreatic Cancer Breakthrough: New Drug Shows 94% Survival Rate vs 67% Standard Care in Phase 2a Trial - Stock Titan

Jun 17, 2025
pulisher
Jun 16, 2025

Immuneering Corp holds annual stockholder meeting By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Immuneering Corp holds annual stockholder meeting - Investing.com Australia

Jun 16, 2025
pulisher
Jun 16, 2025

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - The Manila Times

Jun 16, 2025
pulisher
Jun 16, 2025

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - GlobeNewswire Inc.

Jun 16, 2025
pulisher
Jun 13, 2025

Two Sigma Investments LP Purchases 10,126 Shares of Immuneering Co. (NASDAQ:IMRX) - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Immuneering Co. (NASDAQ:IMRX) Stock Position Reduced by Millennium Management LLC - Defense World

Jun 12, 2025
pulisher
Jun 06, 2025

Immuneering’s (IMRX) Buy Rating Reaffirmed at Needham & Company LLC - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Needham Maintains Buy Rating on IMRX with Price Target of $9.00 - GuruFocus

Jun 05, 2025
pulisher
May 29, 2025

Full Immuneering Leadership Team Reveals Latest Pipeline Updates at Prestigious Jefferies Conference - Stock Titan

May 29, 2025
pulisher
May 15, 2025

‘Take the Plunge,’ Says Top Investor About Intel Stock - The Globe and Mail

May 15, 2025
pulisher
May 07, 2025

Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.0 - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst | IMRX Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

21,432 Shares in Immuneering Co. (NASDAQ:IMRX) Acquired by Marshall Wace LLP - Defense World

May 07, 2025
pulisher
May 07, 2025

Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.00 | IMRX Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Immuneering Corp. Reports Promising Q1 2025 Results - TipRanks

May 07, 2025
pulisher
May 06, 2025

Immuneering (IMRX) Stock Rating and Price Target Update | IMRX S - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Immuneering reports Q1 EPS (42c), consensus (58c) - TipRanks

May 06, 2025
pulisher
May 06, 2025

Immuneering (IMRX) Stock Rating and Price Target Update | IMRX Stock News - GuruFocus

May 06, 2025
pulisher
May 05, 2025

Immuneering Corp SEC 10-Q Report - TradingView

May 05, 2025
pulisher
May 05, 2025

Immuneering Reports Breakthrough: Cancer Drug Achieves 13-Month Survival in Late-Stage Pancreatic Cancer Patient - Stock Titan

May 05, 2025
pulisher
May 04, 2025

IMRXImmuneering Corp Latest Stock News & Market Updates - Stock Titan

May 04, 2025
pulisher
May 01, 2025

Charting the Course: Immuneering Corp’s IMRX Stock Prospects - investchronicle.com

May 01, 2025
pulisher
May 01, 2025

What technical indicators reveal about IMRX stock - uspostnews.com

May 01, 2025
pulisher
Apr 30, 2025

Immuneering Co. (NASDAQ:IMRX) Short Interest Update - Defense World

Apr 30, 2025
pulisher
Apr 05, 2025

Immuneering Co. (NASDAQ:IMRX) Shares Bought by HighTower Advisors LLC - Defense World

Apr 05, 2025
pulisher
Apr 02, 2025

Full Executive Team Reveals Next Growth Phase at Major Healthcare Conference - Stock Titan

Apr 02, 2025
pulisher
Mar 28, 2025

Chardan Capital Weighs in on Immuneering FY2025 Earnings - Defense World

Mar 28, 2025
pulisher
Mar 23, 2025

Immuneering’s (IMRX) “Buy” Rating Reaffirmed at Needham & Company LLC - The AM Reporter

Mar 23, 2025
pulisher
Mar 23, 2025

Needham & Company LLC Reaffirms “Buy” Rating for Immuneering (NASDAQ:IMRX) - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

Immuneering Corp. Reports Promising Cancer Trial Results - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

Immuneering Strengthens Leadership: New CMO Joins with $212K Stock Option Grant - StockTitan

Mar 21, 2025
pulisher
Mar 20, 2025

Immuneering reports Q4 EPS (58c), consensus (44c) - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Immuneering Corp SEC 10-K Report - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Immuneering Corporation Q4 Net Income USD 18.1 Million -March 20, 2025 at 04:54 pm EDT - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

Immuneering Breakthrough: New Cancer Drug Doubles Standard Treatment Success Rate - StockTitan

Mar 20, 2025
pulisher
Mar 20, 2025

Immuneering appoints Igor Matushansky as CMO - The Pharma Letter

Mar 20, 2025
pulisher
Mar 20, 2025

Immuneering appoints new Chief Medical Officer - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Former Ipsen Executive Who Led FDA-Approved Cancer Drug Joins Immuneering as CMO - Stock Titan

Mar 20, 2025

Immuneering Corp Stock (IMRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Immuneering Corp Stock (IMRX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Schall Thomas J.
Director
Jun 17 '25
Buy
2.21
40,485
89,278
43,385
$20.73
price up icon 1.02%
$35.27
price down icon 1.78%
$21.32
price up icon 0.24%
$101.74
price down icon 2.97%
$106.14
price up icon 1.28%
biotechnology ONC
$254.49
price down icon 4.73%
Cap:     |  Volume (24h):